Epigenomic Reprogramming in Inorganic Arsenic-Mediated Gene Expression Patterns During Carcinogenesis by Eckstein, Meredith et al.
University of Kentucky
UKnowledge
Molecular and Cellular Biochemistry Faculty
Publications Molecular and Cellular Biochemistry
3-1-2017
Epigenomic Reprogramming in Inorganic Arsenic-
Mediated Gene Expression Patterns During
Carcinogenesis
Meredith Eckstein
University of Kentucky, mlec222@uky.edu
Rebekah Eleazer
University of Kentucky, rebekah.eleazer@uky.edu
Matthew Rea
University of Kentucky, matthew.rea@uky.edu
Yvonne N. Fondufe-Mittendorf
University of Kentucky, y.fondufe-mittendorf@uky.edu
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/biochem_facpub
Part of the Biochemistry, Biophysics, and Structural Biology Commons, Environmental Health
Commons, Genetics and Genomics Commons, and the Inorganic Chemicals Commons
This Review is brought to you for free and open access by the Molecular and Cellular Biochemistry at UKnowledge. It has been accepted for inclusion
in Molecular and Cellular Biochemistry Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Repository Citation
Eckstein, Meredith; Eleazer, Rebekah; Rea, Matthew; and Fondufe-Mittendorf, Yvonne N., "Epigenomic Reprogramming in Inorganic
Arsenic-Mediated Gene Expression Patterns During Carcinogenesis" (2017). Molecular and Cellular Biochemistry Faculty Publications.
134.
https://uknowledge.uky.edu/biochem_facpub/134
Epigenomic Reprogramming in Inorganic Arsenic-Mediated Gene Expression Patterns During Carcinogenesis
Notes/Citation Information
Published in Reviews on Environmental Health, v. 32, issue 1-2, p. 93-103.
©2016, Yvonne Fondufe-Mittendorf et al., published by De Gruyter.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Digital Object Identifier (DOI)
https://doi.org/10.1515/reveh-2016-0025
This review is available at UKnowledge: https://uknowledge.uky.edu/biochem_facpub/134
Rev Environ Health 2017; 32(1-2): 93–103
*Corresponding author: Yvonne Fondufe-Mittendorf, PhD, 
Department of Cellular and Molecular Biology, University of 
Kentucky, BBSRB 273 741, S. Limestone Street, Lexington, 
KY 40506, USA, Phone: +(859) 323-0091,  
E-mail: y.fondufe-mittendorf@uky.edu; and Department of 
Molecular and Cellular Biochemistry, University of Kentucky, 
Lexington, KY 40536, USA
Meredith Eckstein, Rebekah Eleazer and Matthew Rea: Department 
of Molecular and Cellular Biochemistry, University of Kentucky, 
Lexington, KY, USA
Review Open Access
Meredith Eckstein, Rebekah Eleazer, Matthew Rea and Yvonne Fondufe-Mittendorf*
Epigenomic reprogramming in inorganic arsenic-
mediated gene expression patterns during 
carcinogenesis
DOI 10.1515/reveh-2016-0025
Received July 12, 2016; accepted August 8, 2016; previously  published 
online October 4, 2016
Abstract: Arsenic is a ubiquitous metalloid that is not 
mutagenic but is carcinogenic. The mechanism(s) by 
which arsenic causes cancer remain unknown. To date, 
several mechanisms have been proposed, including the 
arsenic-induced generation of reactive oxygen species 
(ROS). However, it is also becoming evident that inor-
ganic arsenic (iAs) may exert its carcinogenic effects by 
changing the epigenome, and thereby modifying chro-
matin structure and dynamics. These epigenetic changes 
alter the accessibility of gene regulatory factors to DNA, 
resulting in specific changes in gene expression both at 
the levels of transcription initiation and gene splicing. In 
this review, we discuss recent literature reports describing 
epigenetic changes induced by iAs exposure and the pos-
sible epigenetic mechanisms underlying these changes.
Keywords: alternative splicing; chromatin; DNA methyla-
tion; epithelial-to-mesenchymal transition; histones.
Introduction
Inorganic arsenic (iAs) is a naturally occurring toxic met-
alloid to which humans are routinely exposed to the envi-
ronment. It is widely distributed in the earth’s crust and is 
ubiquitous in soil, water, and air. Humans are chronically 
exposed to iAs through contaminated food and drinking 
water (1, 2). It is estimated that contaminated wells, formed 
from proximity to iAs-rich geological formations, expose 
160 million individuals worldwide to excessive levels 
of iAs (1) which is over the US environmental protection 
agency’s guideline of 10 ppb (3). The long-term effects of 
low-dose iAs exposure from contaminated drinking water 
continue as mining efforts, which release high amounts of 
iAs into the groundwater, persist in many regions of the 
world (1, 4). While not genotoxic, arsenic and iAs com-
pounds are listed as known human carcinogens by the 
National Toxicology Program (2). Epidemiological studies 
demonstrate a strong relationship between environmen-
tal iAs exposure and an increased cancer incidence. Such 
exposure correlates with an increased risk of lymphatic 
(5), hemtatopoietic (6), skin, lung (5–7), digestive tract 
(5), liver (6), urinary tract (6, 8, 9), and prostate (5, 6) 
cancers. Although the precise mechanisms by which iAs 
causes cancer remain elusive, several mechanisms have 
been proposed. These mechanisms include iAs-induced 
oxidative stress, inhibition of DNA repair, micronuclei 
formation, chromosomal aberrations, and changes to the 
epigenome. This review will focus on proposed epigenetic 
mechanisms that contribute to iAs-induced carcinogen-
esis; however iAs generally, might be effecting similar epi-
genetic mechanisms during pathogenesis. 
Proposed mechanisms of 
 iAs-mediated carcinogenesis 
and toxicity
A variety of mechanisms may contribute to the carci-
nogenicity caused by iAs. One mechanism involves the 
iAs-induced production of reactive oxygen species (ROS) 
which has been reported in multiple cell models includ-
ing human lung bronchial epithelial BEAS-2B cells, human 
vascular smooth muscle cells, vascular endothelial cells, 
U937 cells, NB4 cells, human-hamster hybrid cells, CHO-K1 
cells, and HEL30 cells (10–16). The impact of iAs on ROS 
production is hypothesized to occur in two steps. First, 
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iAs initiates production of high ROS levels, which chemi-
cally react with DNA. This reaction damages the DNA and 
disrupts its structural integrity; thus, contributing to cel-
lular transformation and tumor proliferation (17). NADPH 
oxidase (NOX) has been implicated as the primary source 
for the generation of O2 (18, 19). Though iAs is not able to 
induce the expressions of p47, p67, p91, and several scaf-
folding proteins of the NOX complex, it is, however, able 
to stimulate enzyme activity of NOX by inducing the phos-
phorylation and translocation of p47 (18, 20). Second, cells 
react to the increased amounts of ROS by overexpressing 
the antioxidant enzymes superoxide dismutase, catalase, 
and glutathione, which protect cells against apoptosis. The 
decreased apoptosis and accumulation of damaged cells 
increases carcinogenic potential (17).
Chromosomal instability and epigenetic modifications 
may also play roles in the carcinogenicity of iAs. At low 
doses, iAs does not cause DNA base pair mutations; instead, 
it is known to generate double-stranded breaks (21), which 
results in large-scale chromosomal aberrations (22). Inter-
estingly, iAs exposure results in the impairment of proteins 
involved in base excision repair such as apurinic/apyrimi-
dinic (abasic) endonuclease (APEX1), DNA ligase 1 (LIG1), 
DNA ligase 3 (LIG3), oxo-guanine glycosylase (OGG1), 
poly(ADP) ribose polymerase (PARP1), and DNA polymer-
ase β (POLB) [reviewed in (23)]. The iAs-mediated chromo-
somal instability occurs frequently at centromeres, leading 
to the formation of acentric chromosomes or the fusion of 
centromeres between two chromosomes (24). Fusion of 
two chromosomes at their centromeres can cause improper 
chromosome segregation, which results in aneuploidy or 
in micronuclei formation (21, 25). However, a fusion that 
occurs at chromosomal ends may result in the formation 
of ring-like structures and/or participate in abnormal sister 
chromatid exchanges (24, 26); both of which are deleteri-
ous to the cell. While these are large-scale chromosomal 
rearrangements, iAs also effects changes to chromatin 
structure at the nucleosome level; these changes alter local 
chromatin conformation that ultimately fine-tune the iAs-
mediated gene expression profile.
Eukaryotic DNA is packaged in the form of chroma-
tin, which has a basic repeating unit, the nucleosome. 
Each nucleosome consists of 147 DNA base pairs wrapped 
around two molecules each of four canonical histones 
(histones H2A, H2B, H3, and H4). The tails of these his-
tones are subject to a variety of post-translational modifi-
cations (PTMs) (27, 28), which are dynamically regulated to 
control the accessibility of chromatin to factors that direct 
gene expression. Histone PTMs, other epigenetic marks 
(e.g. methylated DNA or distinctly-combined histone vari-
ants), and microRNAs (miRNAs) are collectively known as 
epigenetic regulators. The remainder of this review will 
focus on the most recent studies that investigate the role 
of iAs exposure in reprogramming these epigenetic marks, 
and how this reprogramming may mediate iAs toxicity.
DNA methylation
DNA methylation is one of the several epigenetic mecha-
nisms that cells use to control gene expression. The effect 
of DNA methylation on a gene’s expression depends on 
the type of regulatory element at which the methylation 
occurs. For instance, methylation of a promoter is associ-
ated with gene repression. However, methylation within 
the gene body is generally associated with gene expres-
sion and splice regulation, although the latter processes 
are poorly understood.
The results of several studies have implicated aber-
rant DNA methylation in many cancers but our under-
standing of the impact of iAs on DNA methylation is just 
emerging (29–31). For instance, Zhao et  al. showed that 
chronic, low-dose exposure of cells to iAs for 18 weeks 
caused global hypomethylation. Other studies revealed 
that iAs exposure to human skin led to global hypometh-
ylation of some tissues (leukocytes), and iAs exposure in 
rodent liver instigated hypomethylation (32, 33). However, 
other research indicates that iAs exposure leads to hyper-
methylation at the promoters of specific tumor-suppressor 
genes, resulting in their repression (34, 35). For example, 
in iAs-exposed human hepatocytes, significant hyper-
methylation of the promoters for genes involved in DNA 
repair such as excision repair cross-complementation 
group 2 (ERCC2) and replication protein A1 (RPA1), and of 
genes associated with the Wnt pathway like c-MYC (MYC) 
and Wnt family member 2B (WNT2B), were observed (34). 
Additionally, significant hypermethylation of the promot-
ers for the tumor suppressor p16 (36, 37), and the DNA 
repair gene, mutL homolog 1 (MLH1) (36), were observed 
in whole blood obtained from humans chronically 
exposed to iAs. Conversely, iAs-induced hypomethylation 
of promoters for genes involved in processes such as endo-
cytosis and RNA transport were also observed (34). Inter-
estingly, another study involving chronic exposure of a 
human population to arsenic demonstrated hypomethyla-
tion at the promoter of the DNA repair gene, ERCC2 (38).
While these findings may at first seem incongruous, 
it is now clear that, although global hypomethylation 
occurs, modifications at specific genetic loci can also be 
either hypo or hypermethylated. Furthermore, it is pos-
sible that some of these disparities may be explained by 
the use of different model systems, different stages of 
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malignant transformation, and different experimental 
conditions (e.g. the dose of iAs, the duration of iAs expo-
sure, and the presence or absence of other carcinogens). 
For instance, Pilser et al. suggested that folate can influ-
ence iAs-mediated DNA methylation profiles in periph-
eral blood leukocytes taken from Bangladeshi adults (33). 
Overall, though, these studies suggest that iAs-mediated 
malignant transformations result from multiple changes 
in DNA methylation patterns and that these altered pat-
terns can have positive or negative effects on the expres-
sion of specific genes. One should be cautious when 
drawing general conclusions about observed iAs-induced 
changes in DNA methylation patterns from any one study. 
Most importantly, profiling should be performed together 
with analyses of the functional consequences of such 
changes in DNA methylation.
Researchers have proposed several possible mecha-
nisms for iAs-mediated changes in DNA methylation. In 
humans, DNA methylation is initiated by the de novo DNA 
methyltransferase 3 (DNMT3A and B) and maintained 
by DNA methyltransferase 1 (DNMT1) (39). Following 
low-dose iAs exposure, the expression of the DNMTs is 
reduced, which results in less methylation at target sites 
(40–42). Because DNMTs also participate in DNA repair, 
inactivation and/or reduction in the expression levels of 
DNA methyltransferases will also impede DNA repair effi-
ciency (35, 41, 43, 44). Another possible explanation for 
iAs-mediated alterations in DNA methylation involves 
the depletion of methyl groups. When cells metabolize 
arsenic, the arsenic methyltransferase, AS3MT, trans-
fers a methyl group from S-adenosylmethionine (SAM) to 
the arsenite (34), depleting the available methyl groups 
needed by the DNMTs for DNA methylation (41). This com-
petition for methyl groups affects DNA methylation sup-
ported by DNMTs, but also the histone methyltransferases. 
As the name implies, these enzymes methylate histones 
and, likewise, are important components of epigenetic 
regulation. Interestingly, there is interplay between DNA 
methylation and histone modification; thus, an imbalance 
in one epigenetic mark could also trigger other  epigenetic 
changes at specific gene regulatory regions.
Histone modifications
PTMs of the N-terminal tails of histone proteins change 
the chromatin structurally and functionally, thereby alter-
ing gene expression. Histone PTMs include methylation, 
acetylation, phosphorylation, glycosylation, carbonyla-
tion, ubiquitylation, biotinylation, sumoylation, citrul-
lination, ADP-ribosylation, N-formylation, crotonylation, 
propionylation, and butyrylation, as well as proline 
and aspartic acid isomerization. The sum of all of these 
histone PTMs is known as the histone code (45). Histone 
PTMs permit, increase or restrict access to chromatin by 
gene regulatory factors. Among the many that have been 
identified, the most extensively studied and best-under-
stood histone PTMs in the context of transcriptional com-
petency are phosphorylation, methylation, acetylation, 
and ubiquitination (46).
Several in vitro studies have demonstrated that iAs 
exposure can result in global changes in histone PTMs. 
These changes include increases in H3K9me2, H3K4me3, 
and H3S10, decreases in H2B ubiquitination, and either 
increases or decreases in H3K27me3 (47–52). In addition, 
following iAs exposure in humans, blood cells exhibited 
an overall decrease in H3K9me3 and H3K9ac, with an 
increase in H3K9me2 (47, 48). Interestingly, these studies 
also showed that the iAs-induced changes in histone 
PTMs can be gender-specific. For instance, a decrease 
in H3K27ac and H3K18ac and increase in H3K4me3 and 
H3K27me3 was observed in iAs-exposed females, while 
the inverse trend was observed in iAs-exposed males (47).
The majority of PTMs that affect chromatin accessi-
bility are modifications to histone H3 (e.g. H3K4, H3K9, 
H3K27, and H3K36). Methylation of H3K4 is performed by a 
series of type 2 lysine methyltransferases (KMT2) (53) and 
occurs in a stepwise manner; methylation proceeds from 
the mono- to the di- and, finally, to the tri-methylation 
state. These different H3K4me states vary in their genomic 
distributions: H3K4me1 occurs at the 3’ end of genes, 
H3K4me2 occurs within the gene body, and H3K4me3 
occurs at gene promoters (53). Deposition of H3K4me3 at 
gene promoters and coding regions correlates with tran-
scriptional activation (50, 54, 55). Exposure of cells to iAs 
results in a global decrease in monomethylated H3K4, 
with a corresponding increase in H3K4’s di- and tri-meth-
ylated states (50). This shift in the global H3K4 methyla-
tion status occurs quickly; exposing cells to 1 μM iAs led to 
the changes in H3K4 methylation states in as little as 24 h 
(50). Furthermore, Tyler et al. found that perinatal arsenic 
exposure resulted in changes to H3K9Ac and H3K4me3 
levels in the brains of adult mice (56, 57).
Analogous to H3K4 methylation, H3K9 is first mono-
methylated and then dimethylated by euchromatic his-
tone-lysine N-methyltransferase 2 (KMT1C, also known as 
G9a). Suppressor of variegation 3–9 homolog 1 (KMT1A, 
also known as SUV39h1) then converts the di-methylated 
state further to the tri-methylated state by (49, 58). These 
methylation events are offset by lysine demethylase 3A 
(KDM3A), a histone demethylase that reverses the mono- 
or di-methylation of H3K9 (49). Like methylated H3K4, the 
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di- and tri-methylated states of H3K9 are typically found 
in different chromatin locations; H3K9me2 tends to local-
ize at the edges of the nucleus, where heterochromatin is 
more common, while H3K9me3 is found in the center of 
the nucleus, where euchromatin predominates (49, 50). 
Exposure of A549 lung carcinoma cells to iAs increased 
expression of KMT1C, leading to an increase in H3K9me2 
and H3K9me3 levels (49). Furthermore, Chervona et  al. 
observed a variety of correlations between iAs exposure 
and this type of modification in peripheral blood mono-
nuclear cells using a population-based study in Bangla-
desh. This study further revealed a positive correlation 
between urinary iAs and H3K9me2 (47, 59).
H3K27 methylation is another important PTM for 
histone H3. This repressive PTM is mediated by the poly-
comb repressive complex 2 (PRC2); PRC2 is composed of 
three core components: Enhancer of Zeste 1 or 2 (EZH1/2), 
suppressor of Zeste 12 (SUZ12), and embryonic ectoder-
mal development (EED). The methylation state conferred 
by PRC2 is determined by the homolog of EZH present in 
the complex – EZH1 mediates the monomethylation of 
H3K27, while EZH2 mediates its di- and tri-methylation. 
H3K27me3 is associated with inactive promoters and 
gene silencing and, importantly, it marks chromatin for 
further compaction by protein regulator of cytokinesis 
(PRC1) via ubiquitylation of H2AK119 (60). The iAs expo-
sure greatly increases the expression of the EZH2 homolog 
and of other PRC2 core components, resulting in a global 
increase in H3K27me3 levels (51). A persistent increase in 
EZH2 and the subsequent incorporation of H3K27me3 into 
chromatin silences the promoters of target genes, which 
is enhanced by the crosstalk that occurs between epige-
netic marks. A clear example of this cross-talk is seen by 
the reduced expressions of p19ARF and p16INK4a due to 
the incorporation of H3K27me3 and H3K9me2, and to the 
methylation of DNA at the INK4/ARF regulatory locus in 
iAs-exposed cells (37, 61, 62).
It is well known that many changes in histone marks 
are mediated by histone kinases. The kinase-mediated 
phosphorylation of histone H3 is one example that is 
associated with cell proliferation and transformation (63, 
64). With regard to arsenic exposure, it is likely that iAs 
activates a cell signaling pathway that modifies histones. 
For example, iAs induces the activation of the nuclear 
mitogen and stress-activated protein kinase 1 (MSK1) via 
the p38 MAPK pathway (29, 65), and this process was 
necessary for iAs-induced transformation (66). Interest-
ingly, in response to stress, MSK1 phosphorylates KDM3A 
(p-KDM3A) at Ser264, resulting in the enrichment and 
recruitment of signal transducer and activator of transcrip-
tion 1 (STAT-1) and p-KDM3A to target gene promoters. 
These events promote the localized demethylation of H3K9 
with consequential increased transcriptional activity (67). 
Additionally, MSK1 can directly phosphorylate H3S10 (68, 
69), which recruits scaffolding proteins to the promot-
ers of immediate-early genes, including those of proto- 
oncogenes FOS and JUN, to induce their activation (70).
Only a few studies have demonstrated a connection 
between histone phosphorylation and arsenic-induced 
carcinogenicity. Studies have suggested that arsenic-
induced H3 phosphorylation might be responsible for the 
up-regulation of the oncogenes c-fos and c-jun (65). Most 
recently, Ray et  al. reported that iAs induces a coordi-
nated regulation of Nrf2 and histone H3S10 phosphoryla-
tion, which activates the human heme oxygenase-1 gene 
(HMOX1) (52). These results reinforce the notion that iAs 
modulates gene expression by operating through the JNK 
and p38/Mpk2 kinase pathway to promote cancer.
The iAs may also modulate histone PTMs by activating 
the epidermal growth factor (EGF) pathway (71). Upon acti-
vation of this pathway, pyruvate kinase, muscle 2 (PKM2) – 
a histone kinase – translocates to the nucleus, where it 
binds and phosphorylates Thr11 on histone H3 (H3T11). 
This phosphorylation not only accelerates the demethyla-
tion of H3K9me3 by the trimethylation-specific H3 methy-
lase KDM4C but also leads to the dissociation of HDAC3, 
allowing the acetylation of H3 with subsequent transcrip-
tion of oncogenes MYC and cyclin D1 (CCND1) (72). By 
influencing this pathway, iAs may indirectly control the 
phosphorylation and acetylation state of histones, and 
therefore the expression patterns of target genes.
Histone variants
In addition to the four canonical histones, there are also 
highly conserved variants of these histones. The variants 
differ by only a few amino acids, and their expression is 
generally lower than the canonical histones. Each histone 
variant has a specific gene expression, and a distinct chro-
matin localization/incorporation that confers, within the 
chromatin structure, information specifying the cell-type, 
the stage of differentiation and tissue. However, compared 
to the canonical histones, studies on histone variants are 
limited, and so the role these chromatin-incorporated 
histone variants play in normal cells and even in diseased 
states is only beginning to emerge. Our understanding 
of the impact these histone variants have on chromatin 
biology is hindered by a lack of high-resolution and sen-
sitive assays to differentiate these proteins, as they have 
a very similar amino acid composition to canonical his-
tones. However, using high-resolution Top-down mass 
Eckstein et al.: iAs-mediated epigenomic reprogramming      97
spectrometry, recent studies from our laboratory showed 
that some histone variants were dynamically altered 
during iAs-mediated malignant transformation. Specifi-
cally, we showed that histone H2B variants were abnor-
mally expressed following iAs exposure, and during the 
subsequent iAs-mediated epithelial-mesenchymal transi-
tion (EMT) (73). We identified a total of 16 H2B variants, 13 
somatic and three testis-specific; of the somatic variants, 
seven were upregulated while three were downregulated 
(73–77). The most significant changes observed in our 
study were the upregulation of histones H2B1K and H2B1C, 
and downregulation of histones H2B1D and H2B1B. The 
results demonstrated that although histones are highly 
conserved, changes in single amino acids can influence 
chromatin dynamics that lead to transcriptional repro-
gramming critical for cell-type specificity and differentia-
tion (77). Interestingly, removal of iAs returned expression 
levels for some variants to normal levels while others 
remained abnormal, suggesting that some epigenetic 
changes are transient (73). This iAs removal and its associ-
ated reversed gene expression, correlated with a reversal 
in the variant histones expressed during EMT. Therefore, 
it is possible that the carcinogenic potential seen in these 
cells is driven by expression patterns of histone variants 
that did not revert following iAs removal.
The iAs is known to disrupt the balance between 
canonical histone H3.1 and variant histone H3.3. Histone 
H3.1 transcription levels are highest during S phase, while 
H3.3 expression levels are consistently low throughout 
the cell cycle (78–83). Functionally, histone H3.1 is ubiq-
uitously present in genomic chromatin, while histone 
H3.3 is incorporated into DNA promoter regions to specifi-
cally facilitate transcriptional activation (84, 85). The iAs 
treatment increases histone H3.1 stability, hindering the 
interaction of histone H3.3 with chromatin and changed 
nucleosome composition; these effects likely change the 
gene expression patterns (86). Specifically, the irregular 
incorporation of H3.1 could silence tumor-suppressor 
genes and abnormally activate cell-cycle genes. The 
proposed mechanism for this iAs-mediated increased 
influence by H3.1 involves an associated inhibition of 
stem-loop binding protein (SLBP) expression (87, 88). 
Under normal conditions, SLBP binds to the stem-loop 
on histone transcripts preventing their degradation. With 
iAs exposure, SLBP expression levels are reduced allow-
ing more proteasomal degradation of the protein (80, 86). 
With less SLBP present, canonical histone transcripts 
with the stem loop are degraded, leaving those with a 
polyadenylated tail (H3.1) intact. Indeed, the addition of 
a poly(A) tail to histone transcripts increases their sta-
bility so they may be present in higher levels outside of 
S phase. This processing ultimately increases H3.1 levels 
and blocks potential histone H3.3 interactions at strategic 
sites, causing aberrant gene expression (86). Knockdown 
of SLBP caused increased cell growth and transformation, 
indicating that this mechanism may be implicated in arse-
nic-induced carcinogenesis (86).
Other histone variants are implicated in carcinogen-
esis. For example, abnormal expression of histone H2A.X, 
a histone variant involved in double-stranded break 
repair, genome stability, and tumor suppression (89–93) 
has been associated with progression of EMT in colon 
and lung cancer (94, 95). When histone H2A.X levels are 
reduced, the variant is removed from the gene loci for 
Slug and ZEB1 (EMT markers) creating a relaxed chroma-
tin structure and increased expression (94). Upregulation 
of histone H2A.Z, another histone H2A variant, is impli-
cated in colorectal and breast cancer (96–100). Histone 
H2A.Z normally maintains the stability and integrity of 
the genetic material within the cell (101, 102). When this 
variant is upregulated, cell growth and proliferation 
increase by an activation of cell cycle regulators and EMT 
markers such as E-cadherin and fibronectin (94, 96, 103). 
Yet another set of histone H2A isoforms, H2A.1 and H2A.2, 
are repressive and reduce tumorogenesis (104). These 
histone variants typically act as tumor suppressors by hin-
dering the efficiency of transcription factor binding and 
chromatin remodeling at strategic sites (105–108). Finally, 
upregulation of CENP-A, a centromere-specific H3-like 
histone, is thought to increase the incidence of aneuploidy 
and dysregulation of cell cycle-associated genes, and also 
is implicated in cancer (109). Further research is needed 
to determine if iAs-induced carcinogenesis and toxicity 
employ any of these cancer-related histone variants.
MicroRNAs
MicroRNAs (miRNAs) constitute another epigenetic 
mechanism of gene regulation affecting development, 
growth, and the response to stress. Several in vitro and 
human studies demonstrated arsenic-induced altera-
tions in miRNA gene expression. For instance, Marsit 
et  al. showed global increases in miRNA expression in 
response to iAs exposure (110). In addition, miR-222 and 
miR-21 expressions were increased in the peripheral blood 
of steel factory workers (111). In contrast, a study of Hong 
Kong children aged 12–19 years, found decreased expres-
sion of both miR-21 and miR-221 associated with increased 
urinary arsenic and lead levels (112). Furthermore, in a 
pregnancy cohort from Mexico, maternal total urinary iAs 
was associated with the increased expression of 12 miRNAs 
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in infant cord blood. This study utilized genome-wide 
miRNA analysis and suggests that miRNA alterations can 
lead to gene expression changes in progeny (113). Using 
transcriptome-wide next generation sequencing, Yu et al. 
identified expression changes for 36 new miRNAs from 
iAs-tainted rice (114). Another study in plants showed that 
iAs altered the expression of miR167, miR319, and miR854 
(115). Investigations have pursued the function and 
potential mechanism of these microRNAs in iAs toxicity. 
For example, upregulation of microRNA-21 can enhance 
the transformation potential of a cell by targeting pro-
grammed cell-death 4 (PDCD4) (116). Another functional 
mechanism identified is the iAs-mediated transformation 
in p53 (low) HBECs, which can be reversed by zinc finger 
E-box binding homeobox 1 (ZEB1 and ZEB2)-mediated 
increases in the levels microRNA 200b. Also identified, 
iAs-mediated autophagy is supported by microRNA-21-in-
duced PTEN-ERK signaling, and iAs-induced angiogenesis 
occurs through a microRNA425-5p-regulated CCM3 (117). 
With the help of new technology, additional iAs-associ-
ated miRNAs functions and processes will be discovered, 
revealing the regulatory network that mediates iAs toxic-
ity and carcinogenesis.
Alternative splicing
Epigenetic regulation of gene expression occurs at the 
level of transcriptional activation, as discussed above, 
but also through the less investigated process of splicing. 
Alternative splicing (AS) of pre-mRNA occurs in the major-
ity of multi-exon genes and greatly increases the diversity 
of the proteome. Aberrant splicing is known to occur in 
human cancers (118–120), and a proposed mechanism 
is the substitutions of isoforms associated with carcino-
genesis (121), angiogenesis (122), and EMT (123, 124). Epi-
genetic modifications are thought to regulate AS by two 
non-mutually exclusive means: 1) by affecting the kinet-
ics of polymerase elongation and 2) through recruitment 
of splicing regulatory factors. Two types of epigenetic 
marks, DNA methylation (125–128) and histone PTMs (120, 
129–132), have been implicated in the selection of exon-
candidates. Exposure to iAs significantly alters DNA meth-
ylation (133) and histone PTMs (48–50, 62, 134–136), and 
so it is reasonable to expect that this exposure can induce 
changes in alternative splicing. Indeed, we recently 
showed that low-dose iAs exposure results in changes in 
AS (133), though the mechanism remains unknown.
One possible mechanism by which iAs influences AS 
may be through an inhibition of DNA binding by alternative 
splicing regulators such as CCCTC-binding factor (CTCF) 
and poly (ADP) ribose polymerase (PARP1) (132, 137, 138). 
Interestingly, PARP1 co-localizes with CTCF on chromatin; 
this complex, with CTCF-dependent automodification of 
PARP1, permits PARylation activity in the absence of DNA 
damage (137, 139). Importantly, many splicing factors are 
regulated by PARylation (140–144) and any iAs-mediated 
inhibition of PARP1 binding to DNA not only affects the 
structural properties of chromatin but also the PARyla-
tion activities, which indirectly affect splicing decisions. 
In addition, the binding of proteins to DNA can be altered 
by the presence of iAs due to the high binding affinity of 
this metalloid for cysteine residues that are found in C4 
and C3H1 zinc finger motif-containing proteins such as 
PARP1 (145–147). Other DNA-binding proteins with zinc 
finger motifs inhibited by iAs are the methylcytosine diox-
ygenases (TET1/2), needed to oxidize 5-methylcytosine to 
5-hydroxymethylcytosine and 5-carboxylcytosine (148). 
Inactivation of TET1/2 by iAs allows 5-methylcytosine to 
accumulate at CTCF target sites and prevents CTCF from 
binding to its target sites, resulting in exon exclusion (126). 
In summary, if iAs blocks the binding of PARP1 or CTCF to 
DNA, the chromatin-associated functioning of these pro-
teins is altered, which includes splicing decisions.
A second possible mechanism by which iAs may alter 
AS is by increasing the presence of p52 through activation 
of the non-canonical NF-κB pathway (149). P52 co-local-
izes and interacts with the splicing factor SRSF1 to modu-
late splicing (129). The role of SRSF1 in carcinogenesis is 
well studied (150), and its expression is upregulated by 
MYC (151), which in itself is deregulated in iAs exposure 
(34, 152). MYC also directly upregulates core pre-mRNA 
machinery during carcinogenesis and maintains appro-
priate splicing of alternative exons (153).
The dominant isoform expressed for any given gene 
is tissue-specific and may result from differentially 
expressed splicing regulatory factors among tissue types 
(154–156). As changes in AS are likely to vary from tissue 
to tissue, our ability to dissect and understand the compli-
cated issue of what drives iAs-mediated carcinogenesis is 
exacerbated.
Conclusion
A large body of research has implicated low-dose arsenic 
exposure in carcinogenesis and EMT. This review exam-
ines the impact of epigenetic processes, including DNA 
methylation, histone PTMs, histone variants, and alter-
native splicing, on carcinogenesis mediated through iAs 
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exposure. While all of these epigenetic marks are associ-
ated with iAs-induced carcinogenesis, additional research 
is required to clarify the mechanism(s) driving each 
system. Expanded research in this area will delineate the 
role of iAs exposure in the initiation and development of 
cancer. Finally, while this review is on arsenic, it is possi-
ble that other heavy metals act through similar epigenetic 
mechanisms. However, a comprehensive genome-wide 
analysis comparing the effects of toxic metals in a single 
study will help delineate whether similar epigenetic 
mechanisms are targeted by heavy metals.
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